HC Wainwright Reiterates “Buy” Rating for KalVista Pharmaceuticals (NASDAQ:KALV)

HC Wainwright reaffirmed their buy rating on shares of KalVista Pharmaceuticals (NASDAQ:KALV) in a research report sent to investors on Monday morning, Benzinga reports. HC Wainwright currently has a $20.00 target price on the specialty pharmaceutical company’s stock.

Other research analysts also recently issued research reports about the stock. Needham & Company LLC restated a buy rating and set a $32.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, September 6th. Cantor Fitzgerald reiterated an overweight rating on shares of KalVista Pharmaceuticals in a research report on Monday, September 9th.

KalVista Pharmaceuticals Stock Performance

NASDAQ:KALV opened at $10.99 on Monday. The firm’s 50-day moving average is $11.89 and its 200-day moving average is $12.05. KalVista Pharmaceuticals has a 52-week low of $7.21 and a 52-week high of $16.88. The company has a market cap of $463.65 million, a price-to-earnings ratio of -3.23 and a beta of 0.89.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings data on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.91) by $0.04. Equities analysts predict that KalVista Pharmaceuticals will post -3.35 EPS for the current year.

Insider Activity

In other news, CEO Benjamin L. Palleiko sold 14,215 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $12.01, for a total transaction of $170,722.15. Following the sale, the chief executive officer now directly owns 242,527 shares in the company, valued at approximately $2,912,749.27. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 14,215 shares of the company’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $12.01, for a total transaction of $170,722.15. Following the sale, the chief executive officer now directly owns 242,527 shares of the company’s stock, valued at approximately $2,912,749.27. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Paul K. Audhya sold 2,135 shares of the company’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $12.40, for a total transaction of $26,474.00. Following the sale, the insider now directly owns 83,745 shares in the company, valued at $1,038,438. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,804 shares of company stock worth $372,112. Corporate insiders own 12.30% of the company’s stock.

Institutional Trading of KalVista Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD grew its stake in KalVista Pharmaceuticals by 4.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 22,142 shares of the specialty pharmaceutical company’s stock worth $263,000 after buying an additional 944 shares during the last quarter. ClariVest Asset Management LLC grew its stake in KalVista Pharmaceuticals by 2.8% during the second quarter. ClariVest Asset Management LLC now owns 57,096 shares of the specialty pharmaceutical company’s stock worth $673,000 after buying an additional 1,535 shares during the last quarter. Nicholas Investment Partners LP grew its stake in shares of KalVista Pharmaceuticals by 0.9% during the second quarter. Nicholas Investment Partners LP now owns 184,358 shares of the specialty pharmaceutical company’s stock valued at $2,172,000 after purchasing an additional 1,714 shares during the last quarter. nVerses Capital LLC bought a new stake in shares of KalVista Pharmaceuticals during the second quarter valued at approximately $25,000. Finally, The Manufacturers Life Insurance Company grew its stake in shares of KalVista Pharmaceuticals by 27.3% during the second quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company’s stock valued at $182,000 after purchasing an additional 3,314 shares during the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.